Volume 11, Number 6—June 2005
Research
Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococci in Rural Communities, Western United States
Table 4
Comparison of MRSA cases with resistant and susceptible phenotypes*
No (%) |
|||
---|---|---|---|
Resistant group†, N = 142 | Susceptible group‡, N = 32 | p value§ | |
Skin and soft tissue | 74 (52) | 26 (81) | 0.003 |
Urine | 15 (11) | 0 (0) | NS |
Blood | 9 (6) | 1 (3) | NS |
Sputum | 30 (21) | 1 (3) | 0.019 |
Other source | 14 (10) | 4 (13) | NS |
Community-associated | 38 (27) | 24 (75) | <0.0001 |
Sex | |||
Male | 79 (56) | 17 (53) | – |
Female | 63 (44) | 15 (47) | – |
Mean age (y) | 69 | 32 | 0.0001 |
Age >65 y | 89 (63) | 3 (9) | <0.0001 |
Diabetes mellitus | 38 (27) | 1 (3) | 0.002 |
Renal failure | 13 (9) | 0 (0) | NS |
Prior antimicrobial therapy | 61 (43) | 6 (19) | 0.015 |
Immunosuppression | 14 (10) | 0 (0) | NS |
*MRSA, methicillin-resistant Staphylococcus aureus; NS, not significant.
†MRSA isolates resistant to both clindamycin and ciprofloxacin.
‡MRSA isolates susceptible to both clindamycin and ciprofloxacin.
§Based on Fisher exact test. Comparison of age tested by Kruskal-Wallis equality of populations rank test.